Rezultati pretrage - Shanu Modi
- Prikaz rezultata 1 – 20 od 58
- Idi na sljedeću stranicu
-
1
Ganetespib: research and clinical development od Shanu Modi, Komal Jhaveri
Izdano 2015Revisão -
2
HER2 breast cancer therapies: a review od Shanu Modi, Conleth G. Murphy
Izdano 2009Revisão -
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer od Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi
Izdano 2012Artigo -
12
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer od Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias
Izdano 2016Artigo -
13
-
14
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies od Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano
Izdano 2021Revisão -
15
The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation od T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho
Izdano 2015Artigo -
16
A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan od Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi
Izdano 2023Artigo -
17
A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors od Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi
Izdano 2012Artigo -
18
A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer od Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga
Izdano 2013Artigo -
19
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies od Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata
Izdano 2024Artigo -
20
Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer od Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King
Izdano 2012Artigo
Alati za pretragu:
Povezani predmeti
Cancer
Medicine
Internal medicine
Breast cancer
Oncology
Trastuzumab
Metastatic breast cancer
Biology
Cancer research
Adverse effect
Chemotherapy
Gastroenterology
Gene
Pharmacology
Clinical trial
Genetics
Biochemistry
Bioinformatics
Computational biology
Heat shock protein
Hsp90
Paclitaxel
Pertuzumab
Phases of clinical research
Trastuzumab emtansine
Antibody
Clinical endpoint
Drug
Immunology
Lung cancer